Motavizumab

Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants.^[1] As of September 2009^[update], it was undergoing Phase II and III clinical trials.^[2]

Motavizumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	RSV glycoprotein F
Clinical data
Trade names	Numax
Routes of administration	Intravenous
ATC code	J06BD02 (WHO)
Pharmacokinetic data
Protein binding	None
Identifiers
CAS Number	677010-34-3 N
DrugBank	DB06310 Y
ChemSpider	none
UNII	50Y163LK8Q
KEGG	D06621 Y
Chemical and physical data
Formula	C6476H10014N1706O2008S48
Molar mass	145438.16 g·mol−1
NY (what is this?)  (verify)

In June 2010, the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune's request for licensure of motavizumab in a 14 to 3 decision. The members of that panel cited several reasons for the decision, and many were concerned that "we're not looking at a product that has evidence of superiority in terms of efficacy" when compared to the already available monoclonal antibody palivizumab.^[3]

In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development program for motavizumab. The company stated that it would no longer develop motavizumab for the prevention of respiratory syncytial virus (RSV), and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop motavizumab for other treatments of RSV.^[4]